Xiamen Wan Tai is a private enterprise. Xiamen Wan Tai Canghai Biotechnology Co., Ltd. is a wholly-owned subsidiary of Beijing Wan Tai Biopharmaceutical Co., Ltd., a subsidiary of Yangshengtang. It is committed to providing high-quality and affordable innovative vaccines for human disease prevention. Is a private scientific and technological enterprise that develops and produces vaccines. Therefore, Xiamen Wan Tai is not a state-owned enterprise, but a private enterprise. Since its establishment, Xiamen Wan Tai Canghai Biotechnology Co., Ltd. has been deeply involved in the vaccine industry for nearly 20 years, and is committed to providing high-quality and affordable innovative vaccines for human disease prevention. Relying on the "National Research Center for Infectious Disease Diagnostic Reagents and Vaccines Engineering Technology (NIDVD)" jointly established by Yangshengtang and Xiamen University, the Industry-University-Research model of sustainable development was explored, and the world's first technical platform for research and development of recombinant (E.coli) virus particle vaccine was established, and the world's first recombinant hepatitis E vaccine (Yikening) and the world's first cervical cancer vaccine (Hinkening) were successfully developed.